H1-4

Histone H1.4 is a somatic linker histone that compacts chromatin by binding linker DNA—preferentially GC-rich and unmethylated CpG-rich sequences through its C-terminal domain—and is the only somatic H1 variant that forms H1-H1 polymers on oligonucleosomal arrays (PMID:8286360, PMID:8687390, PMID:7848272). Functional reconstitution shows that H1.4 drives formation of compact, stacked nucleosome structures and supports liquid-liquid/liquid-solid phase separation, with its C-terminal tail engaging linker DNA to limit accessibility (PMID:42173878). Its chromatin-binding behavior is tuned by a dense array of post-translational modifications: Aurora B phosphorylates Ser27 in a metaphase-peaking manner to increase H1.4 mobility and evict HP1, which otherwise reads dimethyl-Lys26 via a phospho-switch (PMID:16127177, PMID:21511733); PKA phosphorylates Ser35 to dissociate H1.4 from mitotic chromatin (PMID:21852232); GCN5 acetylates Lys34 at active promoters to increase mobility and recruit general transcription factors (PMID:22465951); CDK9-dependent Ser187 phosphorylation keeps H1.4 at active transcription start sites in stable association with RNA Polymerase II (PMID:33238524); and SET7/9 methylates C-terminal KAK-motif lysines in a manner gated by PARP1/ARTD1 activity (PMID:23289424). Consistent with these roles, H1.4 loss reprograms nascent transcription and chromatin accessibility at AP-1-bound enhancers and biases hematopoietic differentiation (PMID:41054521, PMID:32391789). C-terminal frameshift mutations that produce stable but functionally aberrant nuclear H1.4 cause the neurodevelopmental Rahman syndrome; these mutants fail to compact chromatin or phase separate, reduce proliferation and accelerate senescence, and in neurons downregulate synaptic-signaling genes and reduce neuronal activity (PMID:31447100, PMID:34788807, PMID:42173878).

1. 1994 Medium

   Established the intrinsic DNA-binding preference of H1.4, showing it recognizes GC-rich linker DNA cooperatively through its C-terminal domain rather than binding DNA indiscriminately.

   Evidence DNA melting, gel-shift, and synthetic C-terminal peptide binding assays

   PMID:8286360

   Open questions at the time

   • No structural basis for sequence preference
   • Cooperativity determinant outside the tested 25-residue peptide not mapped
2. 1995 Medium

   Linked H1.4 DNA-binding specificity to epigenetic state by showing it preferentially binds unmethylated CpG-rich DNA and inhibits DNA methylation in vitro, distinguishing it functionally from H1c.

   Evidence In vitro methylation, gel retardation, and Southwestern assays with CpG-rich oligonucleotides

   PMID:7848272

   Open questions at the time

   • In vitro only; no cellular demonstration of methylation regulation
   • Mechanism of methyltransferase inhibition unresolved
3. 1996 Medium

   Identified H1.4 as the unique somatic variant capable of self-polymerization on nucleosomal arrays, implicating it in higher-order chromatin organization, and showed poly(ADP-ribosyl)ation modulates polymer size.

   Evidence Cross-linking, HPLC variant purification, and methyl-accepting assays in native nuclei

   PMID:8687390

   Open questions at the time

   • Functional consequence of polymer formation for chromatin compaction not directly tested in vivo
   • Polymerization interface not mapped
4. 2002 Medium

   Provided structural rationale for linker DNA engagement by showing the H1e N-terminal peptide forms two amphipathic helices joined by a flexible Gly-Gly hinge that could allow DNA tracking or dual-segment binding.

   Evidence CD spectroscopy and 1H-NMR structure determination in TFE

   PMID:11790831

   Open questions at the time

   • Isolated peptide in non-physiological solvent
   • No structure on nucleosomal substrate
5. 2005 High

   Defined a phospho-methyl switch on the H1.4 N-terminal tail in which HP1 reads dimethyl-Lys26 and adjacent Ser27 phosphorylation blocks it, coupling H1.4 modification to heterochromatin reader recruitment.

   Evidence In vitro peptide-binding assays with the HP1 Chromo domain and S27 mutagenesis

   PMID:16127177

   Open questions at the time

   • Kinase responsible for S27 not identified in this study
   • In vivo dynamics of the switch not measured here
6. 2011 High

   Identified the mitotic kinases acting on the H1.4 tail: Aurora B phosphorylates S27 (peaking at metaphase, modulated by K26 methylation) and PKA phosphorylates S35, both reducing H1.4 chromatin binding, connecting the phospho-switch to mitotic chromatin dynamics.

   Evidence In vitro kinase assays, immunofluorescence/immunoblot, FRAP, mutant rescue, and PKA inhibition with compaction readouts

   PMID:21511733 PMID:21852232

   Open questions at the time

   • Phosphatases reversing these marks not identified
   • Interplay between S27 and S35 phosphorylation not resolved
7. 2012 High

   Connected H1.4 to active transcription by showing GCN5-mediated K34 acetylation marks active promoters, increases H1.4 mobility, and recruits a general transcription factor, recasting linker histone modification as activating rather than purely repressive.

   Evidence In vitro acetylation, ChIP-seq for H1.4K34ac, FRAP, and transcription factor recruitment assays

   PMID:22465951

   Open questions at the time

   • Identity of the recruited GTF interaction surface not fully defined
   • Whether K34ac and other marks co-occur on the same molecule unknown
8. 2013 Medium

   Mapped SET7/9 methylation of multiple C-terminal KAK-motif lysines on H1.4 and showed PARP1/ARTD1 ribosylation of H3 gates this methylation, linking H1.4 modification to a broader PARP-dependent regulatory network.

   Evidence In vitro methylation and poly(ADP-ribosyl)ation assays with mass spectrometry site mapping

   PMID:23289424

   Open questions at the time

   • No in vivo validation of the methylation sites
   • Functional consequence of C-terminal methylation untested
9. 2008 Medium

   Demonstrated a host-pathogen role in which H1.4's globular domain binds oligomerized small hepatitis delta antigen and supports HDV replication, the first non-chromatin functional partner identified.

   Evidence TAP-MS, deletion domain mapping, and HDV replication rescue assays

   PMID:18314153

   Open questions at the time

   • Mechanism by which H1.4 promotes HDV replication unclear
   • Single lab, no reciprocal in vivo validation
10. 2019 Medium

    Established H1.4 C-terminal frameshift mutations as causative of a disease state, showing the stable mutant proteins bind chromatin but disrupt compaction, alter methylation, reduce proliferation, and accelerate senescence.

    Evidence Expression of mutant H1.4 with fractionation, DAPI compaction, cell-cycle, senescence, and methylome assays

    PMID:31447100

    Open questions at the time

    • Mechanistic link from compaction defect to senescence not fully resolved
    • Single lab
11. 2020 Medium

    Revealed two distinct in vivo roles: pS187-H1.4 (CDK9-dependent) marks active promoters and binds RNA Pol II, while loss of H1.4 biases myeloid differentiation toward an eosinophil-like program, showing subtype-specific regulatory function.

    Evidence pS187 ChIP-seq and RNAPII co-IP in MCF7; genome-wide CRISPR screen and transcriptional/differentiation profiling in PLB-985 and murine bone marrow

    PMID:32391789 PMID:33238524

    Open questions at the time

    • Direct demonstration that CDK9 phosphorylates S187 not shown
    • How H1.4 loss selects lineage outcome mechanistically unclear
12. 2022 Medium

    Connected the H1.4 C-terminal mutant to the neuronal phenotype of disease by showing it dysregulates ~400 genes, downregulating synaptic and neuropeptide signaling, and reduces neuronal electrical activity.

    Evidence Exogenous WT/mutant H1.4 expression in rat hippocampal neurons with RNA-seq and multielectrode array recording

    PMID:34788807

    Open questions at the time

    • Direct chromatin mechanism at affected neuronal genes not mapped
    • Exogenous overexpression may not model endogenous dosage
13. 2025 Medium

    Placed H1.4 as a regulator of AP-1-directed enhancers, showing its loss alters chromatin accessibility and enhancer histone marks at extragenic/intronic sites with concordant nascent transcription changes.

    Evidence H1.4 knockout with PRO-seq, ATAC-seq, H3K27ac/H3K4me1 ChIP, and motif analysis

    PMID:41054521

    Open questions at the time

    • Whether H1.4 directly opposes AP-1 binding or acts indirectly unclear
    • Single lab
14. 2026 High

    Provided the structural and biophysical mechanism of Rahman syndrome, showing a C-terminal frameshift mutant produces extended nucleosome arrays, increased linker DNA accessibility, failed compaction, impaired phase separation, and higher nuclear mobility.

    Evidence In vitro hexanucleosome reconstitution, cryo-EM/structural analysis, FRET, molecular dynamics, FRAP, and MNase digestion

    PMID:42173878

    Open questions at the time

    • How phase-separation loss translates to specific gene dysregulation not directly linked
    • Effect of disease mutant on PTM-mediated regulation untested

• It remains unknown how the combinatorial array of H1.4 post-translational modifications is integrated on individual molecules to switch between compaction, phase separation, and active-promoter functions, and how disease mutations perturb this integrated code in specific cell types.
• No combinatorial PTM analysis on single molecules
• Phosphatases/demethylases for H1.4 marks unidentified
• Cell-type-specific rules linking H1.4 dosage to gene programs undefined